Treatments being tested
Clinical trials open to people with bowel cancer
Every trial here is a live record from ClinicalTrials.gov, the public registry every trial must be listed on before it starts. Statuses are re-checked against the registry every day or two, because a list that says a closed trial is recruiting is worse than no list at all.
Listing a trial is not a recommendation, and this site has no connection to any of them. Whether a trial is right for you, and whether you would be eligible, is a conversation for your own oncology team.
What these filters mean
Genotype
These are the things that make a tumour unusual, so leave them alone unless one of them is yours. Nothing selected shows every trial. Wild-type and pMMR are the ordinary results and have no button of their own: they would match almost everybody, so they would narrow nothing. Selecting a mutation drops the trials that need the ordinary result instead â which is right, because those are the ones you could not join.
Which KRAS
Only relevant if your tumour is KRAS mutated. Your report will name the exact change, such as G12C or G12D; some newer drugs are built for one specific change and no other.
Each trial is tagged by reading its own eligibility criteria automatically, to make the list searchable. The tags summarise what the criteria mention — they are not a decision about whether you qualify, and where a tag and the criteria disagree, the criteria are right.
57 trials
Recruiting nowPhase 2
Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer
Recruiting nowPhase 2
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Recruiting nowPhase 2
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Recruiting nowPhase 2
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Recruiting nowPhase 2
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Recruiting nowPhase 2
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Recruiting nowPhase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Recruiting nowPhase 2
JS212 Combination Therapies in Metastatic Colorectal Cancer
Recruiting nowPhase 2
Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer
Recruiting nowPhase 2
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
Recruiting nowPhase 2
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
Recruiting nowPhase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Recruiting nowPhase 2
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Recruiting nowPhase 2
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
Recruiting nowPhase 2
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors